iShares Genomics Immunology and Healthcare ETF (IDNA)

iShares Genomics Immunology and Healthcare ETF (IDNA) Finanzdienstleistungsprofil

iShares Genomics Immunology and Healthcare ETF (IDNA) offers investors targeted exposure to companies poised to benefit from long-term growth trends in genomics, immunology, and bioengineering. With a focus on both developed and emerging markets, IDNA provides a diversified investment vehicle for capitalizing on innovation within the healthcare sector, while exhibiting a beta of 1.35.

Investmentthese

The iShares Genomics Immunology and Healthcare ETF (IDNA) presents an investment opportunity centered on the long-term growth potential of genomics, immunology, and bioengineering. The ETF's focus on companies in both developed and emerging markets allows investors to capitalize on global innovation trends within the healthcare sector. With a beta of 1.35, IDNA exhibits moderate volatility relative to the broader market. Key value drivers include the increasing demand for personalized medicine, the development of novel immunotherapies for cancer and other diseases, and the application of bioengineering technologies to address unmet medical needs. Upcoming catalysts include regulatory approvals for new therapies, advancements in genomic sequencing technologies, and increased investment in healthcare infrastructure in emerging markets. Potential risks include regulatory hurdles, clinical trial failures, and competitive pressures from established pharmaceutical companies.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

• Market capitalization of $0.16 billion, indicating a relatively small-cap ETF.
• Beta of 1.35, suggesting higher volatility compared to the broader market.
• Exposure to both developed and emerging market companies in the genomics, immunology, and healthcare sectors.
• Focus on companies that could benefit from long-term growth and innovation in these fields.
• Managed by BlackRock, a leading global asset management firm.

Wettbewerber & Vergleichsunternehmen

Staerken

• Exposure to high-growth sectors: genomics, immunology, and bioengineering.
• Diversified portfolio of companies in both developed and emerging markets.
• Managed by BlackRock, a leading global asset management firm.
• Focus on long-term growth trends in innovative healthcare fields.

Schwaechen

• Relatively small market capitalization, which may limit liquidity.
• Higher beta compared to the broader market, indicating greater volatility.
• Concentration in specific sectors, which may increase risk.
• Dependence on the performance of companies in the genomics, immunology, and healthcare sectors.

Katalysatoren

• Upcoming: Regulatory approvals for new therapies and medical devices.
• Ongoing: Advancements in genomic sequencing and data analytics.
• Ongoing: Increased investment in healthcare infrastructure in emerging markets.
• Ongoing: Growing demand for personalized medicine and innovative treatments.

Risiken

• Potential: Clinical trial failures and setbacks in drug development.
• Potential: Regulatory hurdles and changes in government policies.
• Potential: Economic downturns impacting healthcare spending.
• Ongoing: Competitive pressures from established pharmaceutical companies.
• Ongoing: Market volatility and fluctuations in stock prices.

Wachstumschancen

• Personalized Medicine: The increasing adoption of personalized medicine, driven by advances in genomic sequencing and data analytics, presents a significant growth opportunity for companies in the genomics and healthcare sectors. The global personalized medicine market is projected to reach $2.4 trillion by 2030, growing at a CAGR of 11.2% from 2023. IDNA's exposure to companies involved in genomic sequencing, diagnostics, and targeted therapies positions it to benefit from this trend. Timeline: Ongoing.
• Immunotherapy Advancements: The development of novel immunotherapies for cancer and other diseases is revolutionizing the treatment landscape. The global immunotherapy market is expected to reach $250 billion by 2028, driven by the success of checkpoint inhibitors and CAR-T cell therapies. IDNA's holdings in companies developing and commercializing immunotherapies provide exposure to this high-growth area. Timeline: Ongoing.
• Bioengineering Innovation: Bioengineering technologies, such as gene editing and synthetic biology, are transforming healthcare and creating new opportunities for therapeutic interventions. The global bioengineering market is projected to reach $100 billion by 2027, driven by advancements in CRISPR-Cas9 technology and other gene editing tools. IDNA's exposure to companies involved in gene editing and synthetic biology positions it to capitalize on this emerging field. Timeline: Ongoing.
• Emerging Market Expansion: The increasing healthcare expenditures and growing middle class in emerging markets present a significant growth opportunity for companies in the genomics, immunology, and healthcare sectors. Countries like China and India are investing heavily in healthcare infrastructure and promoting the adoption of innovative therapies. IDNA's exposure to companies with operations in emerging markets allows investors to tap into this growth potential. Timeline: Ongoing.
• Aging Population: The global aging population is driving increased demand for healthcare services and products, particularly in areas such as age-related diseases and chronic conditions. The number of people aged 65 and over is projected to reach 1.6 billion by 2050. IDNA's focus on genomics, immunology, and healthcare aligns with the needs of an aging population, providing exposure to companies developing solutions for age-related health challenges. Timeline: Ongoing.

Chancen

• Increasing adoption of personalized medicine.
• Advancements in immunotherapy and bioengineering technologies.
• Growing healthcare expenditures in emerging markets.
• Aging global population driving demand for healthcare services.

Risiken

• Regulatory hurdles and clinical trial failures.
• Competitive pressures from established pharmaceutical companies.
• Economic downturns impacting healthcare spending.
• Changes in government policies affecting the healthcare industry.

Wettbewerbsvorteile

• Brand recognition and reputation of BlackRock, a leading global asset management firm.
• Diversified portfolio of companies in the genomics, immunology, and healthcare sectors.
• Exposure to both developed and emerging markets.
• Focus on long-term growth trends in innovative healthcare fields.

Ueber IDNA

The iShares Genomics Immunology and Healthcare ETF (IDNA) is designed to provide investors with exposure to companies that are expected to benefit from the ongoing advancements and long-term growth in the fields of genomics, immunology, and bioengineering. Managed by BlackRock, a leading global asset management firm, IDNA seeks to replicate the investment results of an underlying index composed of equities from both developed and emerging markets. The ETF's holdings span a range of companies involved in various aspects of these innovative sectors, including biotechnology firms, pharmaceutical companies, and providers of healthcare services and equipment. IDNA's investment strategy focuses on identifying companies that are at the forefront of genomic research, developing novel immunotherapies, and pioneering bioengineering technologies. By investing in a diversified portfolio of companies within these fields, the ETF aims to capture the potential upside from breakthroughs and advancements that could transform healthcare and improve patient outcomes. The ETF's global reach allows investors to tap into growth opportunities in both established and emerging markets, providing a broader perspective on the evolving landscape of genomics, immunology, and healthcare. As of 2026, IDNA has a market capitalization of $0.16 billion.

Was das Unternehmen tut

• Tracks the investment results of an index composed of developed and emerging market companies.
• Focuses on companies that could benefit from long-term growth and innovation in genomics.
• Targets companies involved in immunology research and development.
• Includes companies engaged in bioengineering technologies.
• Provides investors with exposure to the healthcare sector.
• Offers a diversified portfolio of companies within these innovative fields.
• Aims to capture the potential upside from breakthroughs and advancements in healthcare.

Geschaeftsmodell

• The ETF generates revenue through management fees charged to investors.
• The fund invests in a diversified portfolio of companies in the genomics, immunology, and healthcare sectors.
• The ETF seeks to replicate the investment results of an underlying index.
• The ETF's performance is driven by the growth and innovation of the companies it holds.

Branchenkontext

The asset management industry is characterized by increasing competition, evolving regulatory landscapes, and growing demand for specialized investment products. ETFs like IDNA cater to investors seeking targeted exposure to specific sectors or themes, such as genomics and immunology. The global healthcare market is experiencing rapid growth, driven by factors such as an aging population, rising healthcare expenditures, and technological advancements. IDNA's focus on genomics, immunology, and bioengineering aligns with the broader trend towards personalized medicine and innovative therapies. Competitors in the ETF space include firms offering similar thematic or sector-specific investment products.

Wichtige Kunden

• Individual investors seeking exposure to the genomics, immunology, and healthcare sectors.
• Institutional investors looking for thematic investment opportunities.
• Financial advisors seeking to diversify client portfolios.
• Investors interested in long-term growth potential in the healthcare industry.

Finanzdaten

Chart & Info

Aktuelle Nachrichten

Keine aktuellen Nachrichten fuer IDNA verfuegbar.

Analystenkonsens

MoonshotScore

Haeufige Fragen zu IDNA

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Popular Stocks